Literature DB >> 10842319

Janus kinase 2 is associated with a box 1-like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule-4.

S Chikuma1, M Murakami, K Tanaka, T Uede.   

Abstract

It is a consensus that a cytotoxic T lymphocyte associated molecule-4 (CTLA-4) transduces inhibitory signal for T cell activation under physiological condition, indicating that this molecule is an important regulator of T cell homeostasis in vivo. It has been reported that phosphorylation and dephosphorylation of tyrosine residue Y-165 in the cytoplasmic region of CTLA-4 play an important role in its negative signaling and cell surface expression. Some signaling molecules such as Src homology 2 protein tyrosine phosphatase 2 (SHP-2) and the p85 subunit of phosphatidylinositol 3 kinase (PI3 kinase) associate with phosphorylated tyrosine residue Y-165, through Src homology 2 (SH2) domains. On the other hand, the adapter complex proteins, AP-2 and AP-50 interact with the same tyrosine residue when unphosphorylated, resulting in clathrin-mediated endocytosis of CTLA-4 molecules. The objective of this study is to identify a tyrosine kinase that can directly bind and phosphorylate the critical tyrosine residue, Y-165 in the cytoplasmic domain of CTLA-4. Here, we demonstrated that 1) Janus Kinase 2 (Jak2) was directly associated with a box 1-like motif in the cytoplasmic tail of CTLA-4 molecule, 2) Jak2 phosphorylated Y-165 residue in the cytoplasmic region of CTLA-4 molecule, and 3) Jak2 was associated with CTLA-4 in HUT 78 T cell lines. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10842319

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

Review 1.  CTLA-4 and tolerance: the biochemical point of view.

Authors:  Shunsuke Chikuma; Jeffrey A Bluestone
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity.

Authors:  Andreas Herrmann; Christoph Lahtz; Toshikage Nagao; Joo Y Song; Wing C Chan; Heehyoung Lee; Chanyu Yue; Thomas Look; Ronja Mülfarth; Wenzhao Li; Kurt Jenkins; John Williams; Lihua E Budde; Stephen Forman; Larry Kwak; Thomas Blankenstein; Hua Yu
Journal:  Cancer Res       Date:  2017-07-17       Impact factor: 12.701

Review 3.  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Authors:  Andrew M Intlekofer; Craig B Thompson
Journal:  J Leukoc Biol       Date:  2013-04-26       Impact factor: 4.962

4.  Regulation of human T cell responses by dNP2-ctCTLA-4 inhibits human skin and microvessel graft rejection.

Authors:  Sangho Lim; Nancy C Kirkiles-Smith; Jordan S Pober; Alfred L M Bothwell; Je-Min Choi
Journal:  Biomaterials       Date:  2018-08-21       Impact factor: 12.479

Review 5.  Immune Checkpoint Receptors Signaling in T Cells.

Authors:  Gianluca Baldanzi
Journal:  Int J Mol Sci       Date:  2022-03-24       Impact factor: 5.923

Review 6.  Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy.

Authors:  Gil-Ran Kim; Je-Min Choi
Journal:  Mol Cells       Date:  2022-07-27       Impact factor: 4.250

7.  Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4.

Authors:  Shunsuke Chikuma; John B Imboden; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2003-01-06       Impact factor: 14.307

Review 8.  Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases.

Authors:  Monika C Brunner-Weinzierl; Holger Hoff; Gerd-R Burmester
Journal:  Arthritis Res Ther       Date:  2004-03-03       Impact factor: 5.156

Review 9.  Immune checkpoint signaling and cancer immunotherapy.

Authors:  Xing He; Chenqi Xu
Journal:  Cell Res       Date:  2020-05-28       Impact factor: 25.617

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.